Literature DB >> 8229034

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.

R D Currier1, A F Haerer, E F Meydrech.   

Abstract

An 18-month double-blind treatment of multiple sclerosis with low dose oral methotrexate showed it to be well tolerated and suggested effectiveness in exacerbating-remitting MS but not in the exacerbating progressive and chronic progressive stages.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8229034      PMCID： PMC489824          DOI： 10.1136/jnnp.56.11.1217

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  2 in total

1.  A new scale for evaluating disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1955-08       Impact factor: 9.910

2.  Therapeutic trial of immunosuppressive agents in multiple sclerosis.

Authors:  J W Neumann; D K Ziegler
Journal:  Neurology       Date:  1972-12       Impact factor: 9.910
  2 in total
  11 in total

Review 1.  Outcomes assessment of drug treatment in multiple sclerosis clinical trials.

Authors:  M Malone; B Lomaestro
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

Review 2.  [Cell depletion and myoablation for neuroimmunological diseases].

Authors:  M Diebold; L Kappos; T Derfuss
Journal:  Nervenarzt       Date:  2016-08       Impact factor: 1.214

3.  Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?

Authors:  J Bryant; A Clegg; R Milne
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

Review 4.  Role of immunosuppressive therapy for the treatment of multiple sclerosis.

Authors:  James M Stankiewicz; Hadar Kolb; Arnon Karni; Howard L Weiner
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

5.  Phase II trial of methotrexate in myasthenia gravis.

Authors:  Mamatha Pasnoor; Jianghua He; Laura Herbelin; Mazen Dimachkie; Richard J Barohn
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

6.  [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].

Authors:  V C Zingler; M Strupp; K Jahn; A Gross; R Hohlfeld; T Brandt
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

7.  Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial.

Authors:  Fereshteh Ashtari; Mohammad Reza Savoj
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

8.  A narrative review of psoriasis and multiple sclerosis: links and risks.

Authors:  Annika S Silfvast-Kaiser; Katie B Homan; Bobbak Mansouri
Journal:  Psoriasis (Auckl)       Date:  2019-08-22

Review 9.  Childhood multiple sclerosis: a review.

Authors:  Amy Waldman; Erin O'Connor; Gihan Tennekoon
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2006

Review 10.  Methotrexate for multiple sclerosis.

Authors:  O Gray; G V McDonnell; R B Forbes
Journal:  Cochrane Database Syst Rev       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.